Less than one-third of patients with glaucoma talk to their doctor about the costs of medications needed to control their disease, reports a study in the December issue of Optometry and Vision Science, the official journal of the American Academy of Optometry. The journal is published by Wolters Kluwer.
High costs are an important barrier to regular use of glaucoma medications, and have been linked to more severe disease and faster progression. Doctor-patient communications might be one way to learn about how cost issues affect patients' adherence to using medications as prescribed.
Medication costs are discussed in less than one-third of glaucoma visits, according to the new study by Catherine Slota, PhD, of RTI International, Research Triangle Park, N.C., and colleagues. They encourage vision care professionals to talk about medication costs with their glaucoma patients—especially those without prescription drug coverage, who may be at increased risk of low medication adherence.
Vision Professionals Should Ask About Costs of Glaucoma Medications
Glaucoma is a chronic, incurable eye disease affecting more than 2 million Americans—a number that is expected to rise as the population ages. "Some of the most commonly utilized treatments require lifelong use, requiring high patient adherence to ensure effectiveness," Dr. Slota and coauthors write.
They analyzed video recordings of 275 office visits between glaucoma patients and ophthalmologists, drawn from a larger study of glaucoma communication. The analysis focused on the frequency and nature of communication regarding the cost of glaucoma medications. Most patients had mild glaucoma and were taking a single medication. Nearly all had health insurance, usually including prescription drug coverage.
Overall, the patient and doctor discussed medication costs in about 31 percent of visits. In about five percent of visits, the patient indicated that the cost of glaucoma medications was a problem—mainly patients who did not have medical insurance.
Some patients said that cost issues affected the way they used their glaucoma medications. As one patient said, "Sometime maybe I forget purposely because they're so darn expensive."
In about 18 percent of visits, the physician suggested possible solutions to cost problems, such as switching to a generic or alternative medication. Other suggestions included ordering a three-month supply, working with the pharmacist, or using prescription drug discount programs.
The patient and doctor talked about health insurance or prescription drug coverage in about 15 percent of visits. These conversations were more likely when the patient was starting glaucoma medications for the first time.
The researchers note some limitations of their study—notably including the fact that nearly all of the patients had health and prescription drug insurance. They suggest further studies of cost issues in uninsured patients and other groups at high risk of nonadherence to glaucoma medications.
The results add to previous evidence that few patients discuss the costs of glaucoma medications with their vision care professionals. Dr. Slota and coauthors conclude, "Physicians should consider bringing up medication cost during glaucoma office visits to prompt a discussion of potential cost-related barriers to medication use."
About Optometry and Vision Science
Optometry and Vision Science, official journal of the American Academy of Optometry, is the most authoritative source for current developments in optometry, physiological optics, and vision science. This frequently cited monthly scientific journal has served primary eye care practitioners for more than 90 years, promoting vital interdisciplinary exchange among optometrists and vision scientists worldwide. Michael Twa, OD, PhD, FAAO, of University of Alabama-Birmingham School of Optometry is Editor-in-Chief of Optometry and Vision Science. The editorial office may be contacted at firstname.lastname@example.org.
About the American Academy of Optometry
Founded in 1922, the American Academy of Optometry is committed to promoting the art and science of vision care through lifelong learning. All members of the Academy are dedicated to the highest standards of optometric practice through clinical care, education or research.
About Wolters Kluwer
Wolters Kluwer N.V. (AEX: WKL) is a global leader in information services and solutions for professionals in the health, tax and accounting, risk and compliance, finance and legal sectors. We help our customers make critical decisions every day by providing expert solutions that combine deep domain knowledge with specialized technology and services.
Wolters Kluwer reported 2016 annual revenues of €4.3 billion. The company, headquartered in Alphen aan den Rijn, the Netherlands, serves customers in over 180 countries, maintains operations in over 40 countries and employs 19,000 people worldwide.
Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and the organization, visit http://www.wolterskluwer.com/, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.